3 | 23 Fraunhofer magazine T hey travel by plane, truck or ship, they carry dengue fever and Zika viruses and they’re here to stay: the Asian tiger mosquito. Although it is originally native to the south and south-east Asian tropics and subtropics, climate change is making many parts of Germany feel quite homey for this particular insect. The scientists in project CuliFo are researching where and how these mosquitoes are spreading, as well as what viruses they are bringing along with them and transmitting to humans and animals. Coordinated by the Bernhard Nocht Institute for Tropical Medicine in Hamburg, this interdisciplin- ary team has been on the trail of Aedes albopictus, as the tiger mosquito is known by experts, since 2016. Back then, they only found sporadic signs of the insects in the extreme south west of Germany. Now, how- ever, the tropical mosquitoes have reached or become endemic to large swathes of southern, western and eastern Germany. Since the beginning of this year, the scientists in Germany’s largest joint research project on mosquitoes have been benefiting from the assistance of the Fraun- hofer Institute for Cell Therapy and Immu- nology IZI in Leipzig. “In CuliFo, we are studying the spread of these disease-car- rying insects,” explains Dr. Sebastian Ulbert, head of department for Vaccines and Infection Models. “To do that, we are exam- ining a variety of animals, particularly dead birds, for antibodies that indicate a previ- ous infection caused by a mosquito bite.” Dr. Ulbert and his team obtain samples from all over Germany with the help of their colleagues and close collaboration partners at the Friedrich-Loeffler Federal Research Institute for Animal Health (FLI), which is headquartered on the island of Riems. The researchers’ main focus is the Usutu and West Nile viruses. While Usutu virus is primarily a threat to animals, having caused a sharp decline in the blackbird population in the Upper Rhine region during an outbreak in 2011, West Nile virus also presents a risk to human life. The disease was first identified in 1937 in the West Nile region of Uganda, hence the name. Victims of the virus often expe- rience high fevers, vomiting, diarrhea, exhaustion and joint pain. In some rare cases, it can even lead to inflammation of the brain or the lining of the brain and spi- nal cord — as with tick-borne encephalitis (TBE), which is also caused by a pathogen from the flavivirus family. However, while it is relatively easy to protect yourself against tick bites and so to avoid TBE infec- tions, this is incomparably harder when it comes to mosquito bites — especially as West Nile virus is now being trans- mitted by the common house mosquito. “The West Nile virus is an all-rounder,” says Dr. Ulbert. “It’s not choosy when it comes to the hosts that it can multiply in. We are aware of 350 types of bird alone in which it can replicate. This is why the West Nile virus is the most widely spread mosquito-borne virus in the world.” For- tunately, the same does not hold true for other members of the flavivirus family, like dengue fever and Zika virus. To date, they have almost exclusively used yellow fever mosquitoes as their host and vector. What’s more, these tropical viruses require long, uninterrupted periods of high tem- peratures in order to multiply in the mos- quitoes to such an extent that their bite becomes infectious — another important difference between them and their West Nile cousins, which only need 10 to 15 days where the temperatures do not sink below 20 degrees. This means that the West Nile virus can spread much more quickly. As all flaviviruses resemble each other closely, the antibodies produced by immune cells as a defense against them are also very similar. Consequently, devel- oping test systems that allow for unam- biguous identification is quite a challenge. “The tests that are currently in use often give people a positive result for West Nile virus simply because they have been vaccinated against TBE,” explains Dr. Ulbert. He and his team have succeeded in developing tests that can detect anti- bodies with a far greater level of accuracy. Together with their colleagues at the FLI, the team of researchers aims to improve the testing systems further in project CuliFo so that they can detect the spread of the viruses even more reliably. Their goals include the creation of early warning systems that will allow us to be better prepared for larger outbreaks. The first outbreak of this nature struck the Leipzig region in summer 2020. Ten people were so severely affected by West Nile fever that they had to be treated in intensive care units, and two of the victims died. “Of course, this was during the coro- navirus pandemic, so at the time, no one was interested. There were probably more than a hundred people infected in the city,” Dr. Ulbert estimates. At present, he is working with the University of Leipzig Medical Center to retroactively calculate more accurate figures by screening blood donations. In Padua in northern Italy, the situation is already far more serious. The city experienced an outbreak of the illness last summer, with 200 severely affected patients stretching the local intensive care units to their breaking point. Dozens of those undergoing intensive medical care died. “The case numbers are still quite low for the time being, but they will very probably rise in the years to come, with the areas where they spread expanding within our own borders as well,” predicts Dr. Ulbert. The danger is most severe for older people above the age of 60 and people with preexisting conditions. “The at-risk demographics are much the same as those for coronavirus,” he explains. “However, unlike COVID, we have neither an effective vaccine nor medications to counter West Nile virus.” Currently, all that can be done is to stabilize the patients and hope their immune systems are strong enough to hold out, he adds. Dr. Ulbert and his team are working to change that, and they have already identified a promis- ing vaccine candidate. However, so far, they have not been able to find a partner from the pharmaceutical industry to help them conduct clinical trials. The researchers are also working on a drug that prevents the viruses from replicating in the host cell and could also be used to counter dengue fever and Zika viruses. “It’s still too cold for them in Germany,” says Dr. Ulbert. “But they will come. They have already reached southern Europe.” back to page 1 55 l o r t n o C d n a n o i t n e v e r P e s a e s i D r o f e r t n e C n a e p o r u E : e c n a v d a ’ s t c e s n i e h t f o p a m e h t r o f e c r u o s ; o t o h p k c o t s i / n a g a t n A i , C D C / y n a h t a G s e m a J : o t o h P